Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular diseases, announced the first closing of a Series B financing round of €8.3m.
The financing was led by Vesalius Biocapital II S.A. SICAR and SMS Company Group, along with existing investors KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG (HTGF), The Falck Revocable Trust, Ascenion GmbH and members of the management team.
The funding will be used to support the Phase 1 clinical trial with lead compound OMT-28 for the treatment of atrial fibrillation.
Led by Ulrich Dauer, CEO, and Dr. Robert Fischer, CSO and co-founder, Omeicos is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin which has discovered a series of synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. its OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ, which has a structure optimized to provide high efficacy, safety and oral bioavailability.
OMT-28 has already proven its anti-arrhythmic and cardioprotective potential in different in vivo experimental models. OMEICOS’ synthetic analogs of omega-3 fatty acid epoxides are currently focused on cardiovascular diseases, although they have the potential to be applied across a wide range of diseases.